Journey Medical Corporation DERM announced topline data from the Phase 1 clinical trial assessing the impact of DFD-29 on the microbial flora of healthy adults.
The clinical trial also assessed the safety and tolerability of the treatment. DFD-29 is being developed for papulopustular rosacea in collaboration with Dr. Reddy's Laboratories Ltd RDY.
Rosacea is a chronic, relapsing, inflammatory skin condition commonly presenting with symptoms such as deep facial redness, acne-like inflammatory lesions, and spider veins.
The study achieved all primary objectives and noted no significant safety issues.
Treatment with DFD-29 for 16 weeks did not significantly impact the normal microbial flora and did not induce significant bacterial resistance.
Additionally, treatment with DFD-29 did not cause a significant proliferation of opportunistic organisms. The results indicate that DFD-29 can be safely used for up to 16 weeks with no significant risk of microbiota suppression or development of resistance.
The company anticipates topline data from the Phase 3 trials in June, with a New Drug Application filing subsequently expected in the second half of 2023.
Price Action: DERM shares are up 8.98% at $1.82 on the last check Tuesday.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
